Compare · MYMD vs ORKA
MYMD vs ORKA
Side-by-side comparison of MyMD Pharmaceuticals Inc. (MYMD) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYMD and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.74B, about 45.2x MYMD ($149.1M).
- ORKA has hit the wire 11 times in the past 4 weeks while MYMD has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for MYMD).
- Company
- MyMD Pharmaceuticals Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $149.1M
- $6.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
MyMD Pharmaceuticals Inc.
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
Latest MYMD
- TNF Pharmaceuticals Trades Under New Ticker "TNFA"
- TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
- MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
- MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
- SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Friscia Stephen
- Latest Key Hires & Board Changes In Cannabis Industry: Canopy Growth, Acreage And More
- MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-3 filed by MyMD Pharmaceuticals Inc.
- Amendment: MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update